Michael Morris discusses integrating PSMA PET into high-risk biochemical recurrence, where systemic therapy follows the EMBARK regimen. Dr. Morris treats PSMA-avid oligoprogressive lesions with ...
(UroToday.com) The 2026 ProsTIC annual meeting featured a Lutetium-177 session and a presentation by Dr. Arun Azad discussing appropriate use of 177 Lu-PSMA-617 in 2026. Rather than focusing solely on ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
To compare treatment trends and survival between bladder‑preserving (BP) therapy and radical cystectomy (RC) in patients with T2N0M0 muscle‑invasive bladder cancer (MIBC) using a large ...
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Daniel Moon discussing the PRIMARY 2 study. mpMRI has become an important component of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results